Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/1/18 → 8/31/19 |
Funding
- Ridgeline Therapeutics LLC: $73,363.96
Dose ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes
- Hommel, Jonathan (PI)
Project: Other project